Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Identifieur interne : 000417 ( PubMed/Corpus ); précédent : 000416; suivant : 000418Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Auteurs : Martin J. Van Den Bent ; Brigitta Baumert ; Sara C. Erridge ; Michael A. Vogelbaum ; Anna K. Nowak ; Marc Sanson ; Alba Ariela Brandes ; Paul M. Clement ; Jean Francais Baurain ; Warren P. Mason ; Helen Wheeler ; Olivier L. Chinot ; Sanjeev Gill ; Matthew Griffin ; David G. Brachman ; Walter Taal ; Roberta Rudà ; Michael Weller ; Catherine Mcbain ; Jaap Reijneveld ; Roelien H. Enting ; Damien C. Weber ; Thierry Lesimple ; Susan Clenton ; Anja Gijtenbeek ; Sarah Pascoe ; Ulrich Herrlinger ; Peter Hau ; Frederic Dhermain ; Irene Van Heuvel ; Roger Stupp ; Ken Aldape ; Robert B. Jenkins ; Hendrikus Jan Dubbink ; Winand N M. Dinjens ; Pieter Wesseling ; Sarah Nuyens ; Vassilis Golfinopoulos ; Thierry Gorlia ; Wolfgang Wick ; Johan M. KrosSource :
- Lancet (London, England) [ 1474-547X ] ; 2017.
Abstract
The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.
DOI: 10.1016/S0140-6736(17)31442-3
PubMed: 28801186
Links to Exploration step
pubmed:28801186Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.</title><author><name sortKey="Van Den Bent, Martin J" sort="Van Den Bent, Martin J" uniqKey="Van Den Bent M" first="Martin J" last="Van Den Bent">Martin J. Van Den Bent</name><affiliation><nlm:affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.</nlm:affiliation></affiliation></author><author><name sortKey="Baumert, Brigitta" sort="Baumert, Brigitta" uniqKey="Baumert B" first="Brigitta" last="Baumert">Brigitta Baumert</name><affiliation><nlm:affiliation>Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; Department of Radiation-Oncology, University of Münster, Münster, Germany; Paracelsus Clinic, Osnabrück, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Erridge, Sara C" sort="Erridge, Sara C" uniqKey="Erridge S" first="Sara C" last="Erridge">Sara C. Erridge</name><affiliation><nlm:affiliation>Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Vogelbaum, Michael A" sort="Vogelbaum, Michael A" uniqKey="Vogelbaum M" first="Michael A" last="Vogelbaum">Michael A. Vogelbaum</name><affiliation><nlm:affiliation>Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nowak, Anna K" sort="Nowak, Anna K" uniqKey="Nowak A" first="Anna K" last="Nowak">Anna K. Nowak</name><affiliation><nlm:affiliation>School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; Co-Operative Group for Neuro-Oncology, University of Sydney, Camperdown, NSW, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Sanson, Marc" sort="Sanson, Marc" uniqKey="Sanson M" first="Marc" last="Sanson">Marc Sanson</name><affiliation><nlm:affiliation>Sorbonne Universités UPMC, University Paris VI, INSERM, CNRS, APHP, Institut du Cerveau et de la Moelle (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brandes, Alba Ariela" sort="Brandes, Alba Ariela" uniqKey="Brandes A" first="Alba Ariela" last="Brandes">Alba Ariela Brandes</name><affiliation><nlm:affiliation>Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Clement, Paul M" sort="Clement, Paul M" uniqKey="Clement P" first="Paul M" last="Clement">Paul M. Clement</name><affiliation><nlm:affiliation>Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Baurain, Jean Francais" sort="Baurain, Jean Francais" uniqKey="Baurain J" first="Jean Francais" last="Baurain">Jean Francais Baurain</name><affiliation><nlm:affiliation>Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Mason, Warren P" sort="Mason, Warren P" uniqKey="Mason W" first="Warren P" last="Mason">Warren P. Mason</name><affiliation><nlm:affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Wheeler, Helen" sort="Wheeler, Helen" uniqKey="Wheeler H" first="Helen" last="Wheeler">Helen Wheeler</name><affiliation><nlm:affiliation>Northern Sydney Cancer Centre, North Shore Hospital, St Leonards, NSW, Australia; Department of Medicine, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Chinot, Olivier L" sort="Chinot, Olivier L" uniqKey="Chinot O" first="Olivier L" last="Chinot">Olivier L. Chinot</name><affiliation><nlm:affiliation>Neuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gill, Sanjeev" sort="Gill, Sanjeev" uniqKey="Gill S" first="Sanjeev" last="Gill">Sanjeev Gill</name><affiliation><nlm:affiliation>Department of Medical Oncology, Alfred Hospital, Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Griffin, Matthew" sort="Griffin, Matthew" uniqKey="Griffin M" first="Matthew" last="Griffin">Matthew Griffin</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Brachman, David G" sort="Brachman, David G" uniqKey="Brachman D" first="David G" last="Brachman">David G. Brachman</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Taal, Walter" sort="Taal, Walter" uniqKey="Taal W" first="Walter" last="Taal">Walter Taal</name><affiliation><nlm:affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Ruda, Roberta" sort="Ruda, Roberta" uniqKey="Ruda R" first="Roberta" last="Rudà">Roberta Rudà</name><affiliation><nlm:affiliation>Department of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Weller, Michael" sort="Weller, Michael" uniqKey="Weller M" first="Michael" last="Weller">Michael Weller</name><affiliation><nlm:affiliation>Department of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Mcbain, Catherine" sort="Mcbain, Catherine" uniqKey="Mcbain C" first="Catherine" last="Mcbain">Catherine Mcbain</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Reijneveld, Jaap" sort="Reijneveld, Jaap" uniqKey="Reijneveld J" first="Jaap" last="Reijneveld">Jaap Reijneveld</name><affiliation><nlm:affiliation>VUmc Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Enting, Roelien H" sort="Enting, Roelien H" uniqKey="Enting R" first="Roelien H" last="Enting">Roelien H. Enting</name><affiliation><nlm:affiliation>Department of Neurology, UMCG, University of Groningen, Groningen, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Weber, Damien C" sort="Weber, Damien C" uniqKey="Weber D" first="Damien C" last="Weber">Damien C. Weber</name><affiliation><nlm:affiliation>Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Lesimple, Thierry" sort="Lesimple, Thierry" uniqKey="Lesimple T" first="Thierry" last="Lesimple">Thierry Lesimple</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clenton, Susan" sort="Clenton, Susan" uniqKey="Clenton S" first="Susan" last="Clenton">Susan Clenton</name><affiliation><nlm:affiliation>Weston Park Hospital, Sheffield, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gijtenbeek, Anja" sort="Gijtenbeek, Anja" uniqKey="Gijtenbeek A" first="Anja" last="Gijtenbeek">Anja Gijtenbeek</name><affiliation><nlm:affiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Pascoe, Sarah" sort="Pascoe, Sarah" uniqKey="Pascoe S" first="Sarah" last="Pascoe">Sarah Pascoe</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Herrlinger, Ulrich" sort="Herrlinger, Ulrich" uniqKey="Herrlinger U" first="Ulrich" last="Herrlinger">Ulrich Herrlinger</name><affiliation><nlm:affiliation>Division of Clinical Neuro-Oncology, Department of Neurology, University of Bonn Medical Centre, Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hau, Peter" sort="Hau, Peter" uniqKey="Hau P" first="Peter" last="Hau">Peter Hau</name><affiliation><nlm:affiliation>Wilhelm Sander-Neuro-Oncology Unit and Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Dhermain, Frederic" sort="Dhermain, Frederic" uniqKey="Dhermain F" first="Frederic" last="Dhermain">Frederic Dhermain</name><affiliation><nlm:affiliation>Radiotherapy Department, Gustave Roussy University Hospital, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Van Heuvel, Irene" sort="Van Heuvel, Irene" uniqKey="Van Heuvel I" first="Irene" last="Van Heuvel">Irene Van Heuvel</name><affiliation><nlm:affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Stupp, Roger" sort="Stupp, Roger" uniqKey="Stupp R" first="Roger" last="Stupp">Roger Stupp</name><affiliation><nlm:affiliation>Department of Medical Oncology, University Hospital and University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Aldape, Ken" sort="Aldape, Ken" uniqKey="Aldape K" first="Ken" last="Aldape">Ken Aldape</name><affiliation><nlm:affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Jenkins, Robert B" sort="Jenkins, Robert B" uniqKey="Jenkins R" first="Robert B" last="Jenkins">Robert B. Jenkins</name><affiliation><nlm:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dubbink, Hendrikus Jan" sort="Dubbink, Hendrikus Jan" uniqKey="Dubbink H" first="Hendrikus Jan" last="Dubbink">Hendrikus Jan Dubbink</name><affiliation><nlm:affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Dinjens, Winand N M" sort="Dinjens, Winand N M" uniqKey="Dinjens W" first="Winand N M" last="Dinjens">Winand N M. Dinjens</name><affiliation><nlm:affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Wesseling, Pieter" sort="Wesseling, Pieter" uniqKey="Wesseling P" first="Pieter" last="Wesseling">Pieter Wesseling</name><affiliation><nlm:affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands; Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Nuyens, Sarah" sort="Nuyens, Sarah" uniqKey="Nuyens S" first="Sarah" last="Nuyens">Sarah Nuyens</name><affiliation><nlm:affiliation>EORTC, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Golfinopoulos, Vassilis" sort="Golfinopoulos, Vassilis" uniqKey="Golfinopoulos V" first="Vassilis" last="Golfinopoulos">Vassilis Golfinopoulos</name><affiliation><nlm:affiliation>EORTC, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Gorlia, Thierry" sort="Gorlia, Thierry" uniqKey="Gorlia T" first="Thierry" last="Gorlia">Thierry Gorlia</name><affiliation><nlm:affiliation>EORTC, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Wick, Wolfgang" sort="Wick, Wolfgang" uniqKey="Wick W" first="Wolfgang" last="Wick">Wolfgang Wick</name><affiliation><nlm:affiliation>Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kros, Johan M" sort="Kros, Johan M" uniqKey="Kros J" first="Johan M" last="Kros">Johan M. Kros</name><affiliation><nlm:affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28801186</idno><idno type="pmid">28801186</idno><idno type="doi">10.1016/S0140-6736(17)31442-3</idno><idno type="wicri:Area/PubMed/Corpus">000417</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000417</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.</title><author><name sortKey="Van Den Bent, Martin J" sort="Van Den Bent, Martin J" uniqKey="Van Den Bent M" first="Martin J" last="Van Den Bent">Martin J. Van Den Bent</name><affiliation><nlm:affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.</nlm:affiliation></affiliation></author><author><name sortKey="Baumert, Brigitta" sort="Baumert, Brigitta" uniqKey="Baumert B" first="Brigitta" last="Baumert">Brigitta Baumert</name><affiliation><nlm:affiliation>Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; Department of Radiation-Oncology, University of Münster, Münster, Germany; Paracelsus Clinic, Osnabrück, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Erridge, Sara C" sort="Erridge, Sara C" uniqKey="Erridge S" first="Sara C" last="Erridge">Sara C. Erridge</name><affiliation><nlm:affiliation>Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Vogelbaum, Michael A" sort="Vogelbaum, Michael A" uniqKey="Vogelbaum M" first="Michael A" last="Vogelbaum">Michael A. Vogelbaum</name><affiliation><nlm:affiliation>Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nowak, Anna K" sort="Nowak, Anna K" uniqKey="Nowak A" first="Anna K" last="Nowak">Anna K. Nowak</name><affiliation><nlm:affiliation>School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; Co-Operative Group for Neuro-Oncology, University of Sydney, Camperdown, NSW, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Sanson, Marc" sort="Sanson, Marc" uniqKey="Sanson M" first="Marc" last="Sanson">Marc Sanson</name><affiliation><nlm:affiliation>Sorbonne Universités UPMC, University Paris VI, INSERM, CNRS, APHP, Institut du Cerveau et de la Moelle (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brandes, Alba Ariela" sort="Brandes, Alba Ariela" uniqKey="Brandes A" first="Alba Ariela" last="Brandes">Alba Ariela Brandes</name><affiliation><nlm:affiliation>Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Clement, Paul M" sort="Clement, Paul M" uniqKey="Clement P" first="Paul M" last="Clement">Paul M. Clement</name><affiliation><nlm:affiliation>Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Baurain, Jean Francais" sort="Baurain, Jean Francais" uniqKey="Baurain J" first="Jean Francais" last="Baurain">Jean Francais Baurain</name><affiliation><nlm:affiliation>Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Mason, Warren P" sort="Mason, Warren P" uniqKey="Mason W" first="Warren P" last="Mason">Warren P. Mason</name><affiliation><nlm:affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Wheeler, Helen" sort="Wheeler, Helen" uniqKey="Wheeler H" first="Helen" last="Wheeler">Helen Wheeler</name><affiliation><nlm:affiliation>Northern Sydney Cancer Centre, North Shore Hospital, St Leonards, NSW, Australia; Department of Medicine, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Chinot, Olivier L" sort="Chinot, Olivier L" uniqKey="Chinot O" first="Olivier L" last="Chinot">Olivier L. Chinot</name><affiliation><nlm:affiliation>Neuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gill, Sanjeev" sort="Gill, Sanjeev" uniqKey="Gill S" first="Sanjeev" last="Gill">Sanjeev Gill</name><affiliation><nlm:affiliation>Department of Medical Oncology, Alfred Hospital, Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Griffin, Matthew" sort="Griffin, Matthew" uniqKey="Griffin M" first="Matthew" last="Griffin">Matthew Griffin</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Brachman, David G" sort="Brachman, David G" uniqKey="Brachman D" first="David G" last="Brachman">David G. Brachman</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Taal, Walter" sort="Taal, Walter" uniqKey="Taal W" first="Walter" last="Taal">Walter Taal</name><affiliation><nlm:affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Ruda, Roberta" sort="Ruda, Roberta" uniqKey="Ruda R" first="Roberta" last="Rudà">Roberta Rudà</name><affiliation><nlm:affiliation>Department of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Weller, Michael" sort="Weller, Michael" uniqKey="Weller M" first="Michael" last="Weller">Michael Weller</name><affiliation><nlm:affiliation>Department of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Mcbain, Catherine" sort="Mcbain, Catherine" uniqKey="Mcbain C" first="Catherine" last="Mcbain">Catherine Mcbain</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Reijneveld, Jaap" sort="Reijneveld, Jaap" uniqKey="Reijneveld J" first="Jaap" last="Reijneveld">Jaap Reijneveld</name><affiliation><nlm:affiliation>VUmc Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Enting, Roelien H" sort="Enting, Roelien H" uniqKey="Enting R" first="Roelien H" last="Enting">Roelien H. Enting</name><affiliation><nlm:affiliation>Department of Neurology, UMCG, University of Groningen, Groningen, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Weber, Damien C" sort="Weber, Damien C" uniqKey="Weber D" first="Damien C" last="Weber">Damien C. Weber</name><affiliation><nlm:affiliation>Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Lesimple, Thierry" sort="Lesimple, Thierry" uniqKey="Lesimple T" first="Thierry" last="Lesimple">Thierry Lesimple</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clenton, Susan" sort="Clenton, Susan" uniqKey="Clenton S" first="Susan" last="Clenton">Susan Clenton</name><affiliation><nlm:affiliation>Weston Park Hospital, Sheffield, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gijtenbeek, Anja" sort="Gijtenbeek, Anja" uniqKey="Gijtenbeek A" first="Anja" last="Gijtenbeek">Anja Gijtenbeek</name><affiliation><nlm:affiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Pascoe, Sarah" sort="Pascoe, Sarah" uniqKey="Pascoe S" first="Sarah" last="Pascoe">Sarah Pascoe</name><affiliation><nlm:affiliation>Department of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Herrlinger, Ulrich" sort="Herrlinger, Ulrich" uniqKey="Herrlinger U" first="Ulrich" last="Herrlinger">Ulrich Herrlinger</name><affiliation><nlm:affiliation>Division of Clinical Neuro-Oncology, Department of Neurology, University of Bonn Medical Centre, Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hau, Peter" sort="Hau, Peter" uniqKey="Hau P" first="Peter" last="Hau">Peter Hau</name><affiliation><nlm:affiliation>Wilhelm Sander-Neuro-Oncology Unit and Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Dhermain, Frederic" sort="Dhermain, Frederic" uniqKey="Dhermain F" first="Frederic" last="Dhermain">Frederic Dhermain</name><affiliation><nlm:affiliation>Radiotherapy Department, Gustave Roussy University Hospital, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Van Heuvel, Irene" sort="Van Heuvel, Irene" uniqKey="Van Heuvel I" first="Irene" last="Van Heuvel">Irene Van Heuvel</name><affiliation><nlm:affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Stupp, Roger" sort="Stupp, Roger" uniqKey="Stupp R" first="Roger" last="Stupp">Roger Stupp</name><affiliation><nlm:affiliation>Department of Medical Oncology, University Hospital and University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Aldape, Ken" sort="Aldape, Ken" uniqKey="Aldape K" first="Ken" last="Aldape">Ken Aldape</name><affiliation><nlm:affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Jenkins, Robert B" sort="Jenkins, Robert B" uniqKey="Jenkins R" first="Robert B" last="Jenkins">Robert B. Jenkins</name><affiliation><nlm:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dubbink, Hendrikus Jan" sort="Dubbink, Hendrikus Jan" uniqKey="Dubbink H" first="Hendrikus Jan" last="Dubbink">Hendrikus Jan Dubbink</name><affiliation><nlm:affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Dinjens, Winand N M" sort="Dinjens, Winand N M" uniqKey="Dinjens W" first="Winand N M" last="Dinjens">Winand N M. Dinjens</name><affiliation><nlm:affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Wesseling, Pieter" sort="Wesseling, Pieter" uniqKey="Wesseling P" first="Pieter" last="Wesseling">Pieter Wesseling</name><affiliation><nlm:affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands; Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Nuyens, Sarah" sort="Nuyens, Sarah" uniqKey="Nuyens S" first="Sarah" last="Nuyens">Sarah Nuyens</name><affiliation><nlm:affiliation>EORTC, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Golfinopoulos, Vassilis" sort="Golfinopoulos, Vassilis" uniqKey="Golfinopoulos V" first="Vassilis" last="Golfinopoulos">Vassilis Golfinopoulos</name><affiliation><nlm:affiliation>EORTC, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Gorlia, Thierry" sort="Gorlia, Thierry" uniqKey="Gorlia T" first="Thierry" last="Gorlia">Thierry Gorlia</name><affiliation><nlm:affiliation>EORTC, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Wick, Wolfgang" sort="Wick, Wolfgang" uniqKey="Wick W" first="Wolfgang" last="Wick">Wolfgang Wick</name><affiliation><nlm:affiliation>Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kros, Johan M" sort="Kros, Johan M" uniqKey="Kros J" first="Johan M" last="Kros">Johan M. Kros</name><affiliation><nlm:affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">28801186</PMID><DateCreated><Year>2017</Year><Month>08</Month><Day>12</Day></DateCreated><DateRevised><Year>2017</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>390</Volume><Issue>10103</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.</ArticleTitle><Pagination><MedlinePgn>1645-1653</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(17)31442-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(17)31442-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a phase 3, randomised, open-label study with a 2 × 2 factorial design. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with WHO performance status scores of 0-2. The randomisation schedule was generated with the electronic EORTC web-based ORTA system. Patients were assigned in equal numbers (1:1:1:1), using the minimisation technique, to receive radiotherapy (59·4 Gy in 33 fractions of 1·8 Gy) alone or with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m(2) temozolomide given on days 1-5); or to receive radiotherapy with concurrent temozolomide 75 mg/m(2) per day, with or without adjuvant temozolomide. The primary endpoint was overall survival adjusted for performance status score, age, 1p loss of heterozygosity, presence of oligodendroglial elements, and MGMT promoter methylation status, analysed by intention to treat. We did a planned interim analysis after 219 (41%) deaths had occurred to test the null hypothesis of no efficacy (threshold for rejection p<0·0084). This trial is registered with ClinicalTrials.gov, number NCT00626990.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">At the time of the interim analysis, 745 (99%) of the planned 748 patients had been enrolled. The hazard ratio for overall survival with use of adjuvant temozolomide was 0·65 (99·145% CI 0·45-0·93). Overall survival at 5 years was 55·9% (95% CI 47·2-63·8) with and 44·1% (36·3-51·6) without adjuvant temozolomide. Grade 3-4 adverse events were seen in 8-12% of 549 patients assigned temozolomide, and were mainly haematological and reversible.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Adjuvant temozolomide chemotherapy was associated with a significant survival benefit in patients with newly diagnosed non-co-deleted anaplastic glioma. Further analysis of the role of concurrent temozolomide treatment and molecular factors is needed.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Schering Plough and MSD.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van den Bent</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumert</LastName><ForeName>Brigitta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands; Department of Radiation-Oncology, University of Münster, Münster, Germany; Paracelsus Clinic, Osnabrück, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erridge</LastName><ForeName>Sara C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogelbaum</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowak</LastName><ForeName>Anna K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; Co-Operative Group for Neuro-Oncology, University of Sydney, Camperdown, NSW, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanson</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universités UPMC, University Paris VI, INSERM, CNRS, APHP, Institut du Cerveau et de la Moelle (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandes</LastName><ForeName>Alba Ariela</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clement</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baurain</LastName><ForeName>Jean Francais</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Warren P</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Northern Sydney Cancer Centre, North Shore Hospital, St Leonards, NSW, Australia; Department of Medicine, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chinot</LastName><ForeName>Olivier L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Neuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Alfred Hospital, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brachman</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taal</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudà</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBain</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reijneveld</LastName><ForeName>Jaap</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VUmc Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, VU University Medical Centre, Amsterdam, Netherlands; Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enting</LastName><ForeName>Roelien H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMCG, University of Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Damien C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesimple</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clenton</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Weston Park Hospital, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gijtenbeek</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascoe</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrlinger</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Division of Clinical Neuro-Oncology, Department of Neurology, University of Bonn Medical Centre, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hau</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Wilhelm Sander-Neuro-Oncology Unit and Department of Neurology, University Hospital Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhermain</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Radiotherapy Department, Gustave Roussy University Hospital, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Heuvel</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stupp</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, University Hospital and University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldape</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubbink</LastName><ForeName>Hendrikus Jan</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinjens</LastName><ForeName>Winand N M</ForeName><Initials>WNM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wesseling</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology, VU University Medical Centre, Amsterdam, Netherlands; Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuyens</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>EORTC, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golfinopoulos</LastName><ForeName>Vassilis</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>EORTC, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorlia</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>EORTC, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wick</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kros</LastName><ForeName>Johan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28801186</ArticleId><ArticleId IdType="pii">S0140-6736(17)31442-3</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(17)31442-3</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000417 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000417 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28801186
|texte= Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28801186" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |